Home
report store
neuropathic pruritus postburn itch pipeline insight

Neuropathic Pruritus & Postburn Itch Pipeline Report

Neuropathic Pruritus & Postburn Itch - Pipeline Insight, 2026

Published Date : 2026

Pages : 60

Region : Global,

Summary
TOC Table of Content
LOT
- Sample Request

Loading summary...

1. Report Introduction

2. Neuropathic Pruritus & Postburn Itch

2.1. Overview

2.2. History

2.3. Neuropathic Pruritus & Postburn Itch Symptoms

2.4. Causes

2.5. Pathophysiology

2.6. Neuropathic Pruritus & Postburn Itch Diagnosis

2.6.1. Diagnostic Guidelines

3. Neuropathic Pruritus & Postburn Itch Current Treatment Patterns

3.1. Neuropathic Pruritus & Postburn Itch Treatment Guidelines

4. Neuropathic Pruritus & Postburn Itch - DelveInsight's Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Neuropathic Pruritus & Postburn Itch companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Neuropathic Pruritus & Postburn Itch Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Neuropathic Pruritus & Postburn Itch Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Neuropathic Pruritus & Postburn Itch Late Stage Products (Phase-III)

7. Neuropathic Pruritus & Postburn Itch Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Neuropathic Pruritus & Postburn Itch Discontinued Products

13. Neuropathic Pruritus & Postburn Itch Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report

14. Neuropathic Pruritus & Postburn Itch Key Companies

15. Neuropathic Pruritus & Postburn Itch Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Neuropathic Pruritus & Postburn Itch Unmet Needs

18. Neuropathic Pruritus & Postburn Itch Future Perspectives

19. Neuropathic Pruritus & Postburn Itch Analyst Review

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

List of Tables:

Table 1: Neuropathic Pruritus & Postburn Itch Diagnostic Guidelines
Table 2: Neuropathic Pruritus & Postburn Itch Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Neuropathic Pruritus & Postburn Itch Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Neuropathic Pruritus & Postburn Itch Late Stage Products (Phase-III)
Table 18: Neuropathic Pruritus & Postburn Itch mid Stage Products (Phase-II)
Table 19: Neuropathic Pruritus & Postburn Itch Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products

List of Figures:

Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Neuropathic Pruritus & Postburn Itch companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Neuropathic Pruritus & Postburn Itch Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs

License Type

Offer

neuropathic pruritus postburn itch pipeline insight Sample Page

Get a Sneak Peek at the Latest neuropathic pruritus postburn itch pipeline insight Report

Request Sample

View Pricing

Customize Reports As Per Your Needs

Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

Have a Question?

We are happy to assist you.

+14699457679

info@delveinsight.com

DelveInsight
SUBSCRIPTION
Platform